Contact:
Repros Therapeutics Inc.
Joseph Podolski (281) 719-3447
President and Chief Executive Officer
Repros Announces the Closing of a Registered Direct Offering of Approximately $11.1 Million
THE WOODLANDS, Texas - February 2, 2012 - Repros Therapeutics Inc.® (Nasdaq: RPRX) today announced that they have closed a registered direct offering to sell an aggregate of 2,463,537 shares of common stock for gross proceeds of approximately $11.1 million, before deducting placement agent's fees and estimated offering expenses. Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc. (NYSE AMEX: LTS), acted as the exclusive placement agent for the transaction.
About Repros Therapeutics Inc.
Repros Therapeutics focuses on the development of small molecule drugs for major unmet medical needs that treat male and female reproductive disorders.
Any statements made by the Company that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including the ability to raise additional needed capital on a timely basis in order for it to continue to fund development of its Androxal® and Proellex® programs and have success in the clinical development of its technologies, the reliability of interim results to predict final study outcomes, and such other risks which are identified in the Company's most recent Annual Report on Form 10-K and in any subsequent quarterly reports on Form 10-Q. These documents are available on request from Repros Therapeutics or at www.sec.gov. Repros disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. . Repros disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
For more information, please visit the Company's website at http://www.reprosrx.com.